• Core Technologies

    Leveraging its AI + chemical genomics technology platform, the Company has built an integrated R&D system spanning novel drug molecule discovery, early-stage evalsuation, and clinical development. This platform enables the Company to develop innovative, mechanism-of-action therapies with differentiated clinical profiles in to address significant unmet medical needs.

    800+
    Invention patents applied
    5
    New molecular entity
    projects in development
    2
    Approved marketed products
    11
    Products in clinical
    development stage
    Innovative Product Pipelines
    Committed to developing globally first-in-class and best-in-class original innovative drugs
    The company has two innovative drugs with multiple indications marketed globally and has deployed multiple R&D projects with differentiated advantages and global competitiveness in four major areas: malignant tumors, metabolic diseases, autoimmune diseases, and neurodegenerative diseases.